Granted Patent
B2
US 12,589,165 · App. 16/604,790 · Granted Mar 31, 2026
Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors
Inventors:
Elisabet de los Pinos (Brookline, MA); John Todd Schiller (Kensington, MD); Rhonda C. Kines (Washington, DC)
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services; Aura Biosciences, Inc.
A61K47/6901A61K39/3955A61K41/0061A61K41/0071A61K41/0076A61P35/00C12N7/00A61K2039/54A61K2039/545C12N2710/20023C12N2710/20042C12N2710/20071
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.
Claims (26)
1 . A method for treating a bladder tumor, comprising:
(a) administering to a primary bladder tumor in a subject a composition comprising a virus-like particle conjugate that comprises (i) human papillomavirus capsid proteins and photosensitive molecules, wherein the photosensitive molecules are conjugated to the human papillomavirus capsid proteins, wherein the composition is administered via intralesional injection;
(b) administering to the primary bladder tumor in the subject a composition comprising an immune checkpoint inhibitor selected from anti-PD-1 antibodies, anti-CTLA-4 antibodies, and anti-LAG3 antibodies, wherein the immune checkpoint inhibitor is administered via intravenous or intravesical injection; and
(c) activating the photosensitive molecules using an infrared laser, a near-infrared laser, or an ultraviolet laser.
2 . The method of claim 1 , wherein the human papillomavirus capsid proteins comprise papillomavirus L1 capsid proteins.
3 . The method of claim 2 , wherein the human papillomavirus capsid proteins comprise a combination of human papillomavirus L1 capsid proteins and human papillomavirus L2 capsid proteins.
4 . The method of claim 1 , wherein the virus-like particle conjugate comprises 10 to 1000 photosensitive molecules.
5 . The method of claim 4 , wherein the virus-like particle conjugate comprises about 200 photosensitive molecules.
6 . The method of claim 1 , wherein the photosensitive molecules comprise an infrared (IR) dye.
7 . The method of claim 1 , wherein the photosensitive molecules comprise a near infrared (NIR) dye.
8 . The method of claim 1 , wherein the photosensitive molecules comprise a phthalocyanine dye.
9 . The method of claim 1 , wherein the immune checkpoint inhibitor is pembrolizumab.
10 . The method of claim 1 , wherein the immune checkpoint inhibitor is nivolumab.
11 . The method of claim 1 , wherein the immune checkpoint inhibitor is ipilimumab.
12 . The method of claim 1 , wherein the primary bladder tumor is cancerous.
13 . The method of claim 1 , wherein the primary bladder tumor is a melanoma, carcinoma, sarcoma or lymphoma.
14 . The method of claim 1 , wherein the composition comprising an immune checkpoint inhibitor is administered via intravenous injection.
15 . A method for treating a bladder tumor, comprising:
(a) administering to a primary bladder tumor in a subject a composition comprising a virus-like particle conjugate that comprises (i) human papillomavirus capsid proteins and photosensitive infrared dye molecules, wherein the photosensitive molecules are conjugated to the human papillomavirus capsid proteins, wherein the composition is administered via intralesional injection;
(b) administering to the primary bladder tumor in the subject a composition comprising an immune checkpoint inhibitor selected from pembrolizumab, nivolumab, and ipilimumab, wherein the immune checkpoint inhibitor is administered via intravenous or intravesical injection; and
(c) activating the photosensitive infrared dye molecules using an infrared laser.
16 . The method of claim 15 , wherein the human papillomavirus capsid proteins comprise a combination of human papillomavirus L1 capsid proteins and human papillomavirus L2 capsid proteins.
17 . The method of claim 15 , wherein the virus-like particle conjugate comprises 10 to 1000 photosensitive molecules.
18 . The method of claim 17 , wherein the virus-like particle conjugate comprises about 200 photosensitive molecules.
19 . The method of claim 15 , wherein the primary bladder tumor is a melanoma, carcinoma, sarcoma or lymphoma.
20 . The method of claim 15 , wherein the composition comprising an immune checkpoint inhibitor is administered via intravenous injection.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 17, 2019
From: DE LOS PINOS, ELISABET; KINES, RHONDA C.
To: AURA BIOSCIENCES, INC.
Reel/Frame 051300/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 17, 2019
From: SCHILLER, JOHN TODD
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 051300/0898 →
Continuity (3)
Provisional Application
62484693
· Apr 12, 2017
Related Publication
20220152217A9
· May 19, 2022
References Cited (233)
US 4625014A
· Senter et al.
· 1986
[cited by applicant]
US 4659839A
· Nicolotti
· 1987
[cited by applicant]
US 5126129A
· Wiltrout et al.
· 1992
[cited by applicant]
US 5290551A
· Berd
· 1994
[cited by applicant]
US 5334711A
· Sproat
· 1994
[cited by applicant]
US 5478556A
· Elliott et al.
· 1995
[cited by applicant]
US 5667764A
· Kopia et al.
· 1997
[cited by applicant]
US 5716824A
· Beigelman
· 1998
[cited by applicant]
US 6022522A
· Sweet et al.
· 2000
[cited by applicant]
US 6180389B1
· Douglas et al.
· 2001
[cited by applicant]
US 6416945B1
· McCarthy et al.
· 2002
[cited by applicant]
US 6599739B1
· Lowy et al.
· 2003
[cited by applicant]
US 6719958B1
· Gozzini et al.
· 2004
[cited by applicant]
US 6984386B2
· Douglas et al.
· 2006
[cited by applicant]
US 6991795B1
· Lowe et al.
· 2006
[cited by applicant]
US 7205126B2
· Qiao et al.
· 2007
[cited by applicant]
US 7351533B2
· McCarthy et al.
· 2008
[cited by applicant]
US 7951379B2
· Kuroda et al.
· 2011
[cited by applicant]
US 8394411B2
· Roberts et al.
· 2013
[cited by applicant]
US 9700639B2
· de los Pinos et al.
· 2017
[cited by applicant]
US 9724404B2
· Coursaget et al.
· 2017
[cited by applicant]
US 9855347B2
· de los Pinos et al.
· 2018
[cited by applicant]
US 20030129583A1
· Martin
· 2003
[cited by applicant]
US 20030206887A1
· Morrissey et al.
· 2003
[cited by applicant]
US 20040005338A1
· Bachmann et al.
· 2004
[cited by applicant]
US 20040028694A1
· Young et al.
· 2004
[cited by applicant]
US 20040115132A1
· Young et al.
· 2004
[cited by applicant]
US 20040121465A1
· Robinson
· 2004
[cited by applicant]
US 20040146531A1
· Antonsson et al.
· 2004
[cited by applicant]
US 20050112141A1
· Terman
· 2005
[cited by applicant]
US 20050118191A1
· Robinson et al.
· 2005
[cited by applicant]
US 20050181064A1
· Kuroda
· 2005
[cited by applicant]
US 20060141042A1
· Kuroda
· 2006
[cited by applicant]
US 20060166913A1
· Suzuki
· 2006
[cited by applicant]
US 20060204444A1
· Young et al.
· 2006
[cited by applicant]
US 20060216238A1
· Manchester et al.
· 2006
[cited by applicant]
US 20070059245A1
· Young et al.
· 2007
[cited by applicant]
US 20070059746A1
· Kuroda
· 2007
[cited by applicant]
US 20070258889A1
· Douglas et al.
· 2007
[cited by applicant]
US 20090041671A1
· Young et al.
· 2009
[cited by applicant]
US 20100003326A1
· Vertommen et al.
· 2010
[cited by applicant]
US 20110052496A1
· Cid-Arregui
· 2011
[cited by applicant]
US 20110104051A1
· Francis et al.
· 2011
[cited by applicant]
US 20120015899A1
· Lomonossoff et al.
· 2012
[cited by applicant]
US 20120207840A1
· Aura
· 2012
[cited by applicant]
US 20130071414A1
· Dotti et al.
· 2013
[cited by applicant]
US 20130115247A1
· de los Pinos et al.
· 2013
[cited by applicant]
US 20130116408A1
· de los Pinos
· 2013
[cited by applicant]
US 20130136689A1
· Rohlff et al.
· 2013
[cited by applicant]
US 20140306869A1
· Fujita et al.
· 2014
[cited by applicant]
US 20160024469A1
· Wu
· 2016
[cited by applicant]
US 20180311374A1
· Lobb et al.
· 2018
[cited by applicant]
US 20220387619A2
· de los Pinos et al.
· 2022
[cited by applicant]
US 20240216527A1
· de los Pinos et al.
· 2024
[cited by applicant]
CN 1904012A
· 2007
[cited by applicant]
CN 102481378A
· 2012
[cited by applicant]
CN 102573910A
· 2012
[cited by applicant]
CN 105979967A
· 2016
[cited by applicant]
EP 1491210A1
· 2004
[cited by applicant]
JP 2005527493A
· 2005
[cited by applicant]
JP 200765646A
· 2007
[cited by applicant]
JP 2009532564
· 2009
[cited by applicant]
JP 2012523455A
· 2012
[cited by applicant]
JP 2016531591A
· 2016
[cited by applicant]
WO WO9103162A1
· 1991
[cited by applicant]
WO WO9207065A1
· 1992
[cited by applicant]
WO WO9315187A1
· 1993
[cited by applicant]
WO WO9726270A2
· 1997
[cited by applicant]
WO WO9915630A1
· 1999
[cited by applicant]
WO WO0009673A1
· 2000
[cited by applicant]
WO WO0155393A2
· 2001
[cited by applicant]
WO WO03008573A2
· 2003
[cited by applicant]
WO WO03061696A2
· 2003
[cited by applicant]
WO WO2005051431A1
· 2005
[cited by applicant]
WO WO2005086667A2
· 2005
[cited by applicant]
WO WO2006125997A1
· 2006
[cited by applicant]
WO WO2008048288A2
· 2008
[cited by applicant]
WO WO2008054184A1
· 2008
[cited by applicant]
WO WO2008103920A2
· 2008
[cited by applicant]
WO WO2008140961A2
· 2008
[cited by applicant]
WO WO2010027827A2
· 2010
[cited by applicant]
WO WO2010120266A1
· 2010
[cited by applicant]
WO WO2011039646A2
· 2011
[cited by applicant]
WO WO2013009717A1
· 2013
[cited by applicant]
WO WO2013080187A1
· 2013
[cited by applicant]
WO WO2013119877A1
· 2013
[cited by applicant]
WO WO2014039523A1
· 2014
[cited by applicant]
WO WO2015042325A1
· 2015
[cited by applicant]
WO WO2015075468A1
· 2015
[cited by applicant]
WO WO2015120363A1
· 2015
[cited by applicant]
WO WO2015142675A2
· 2015
[cited by applicant]
WO WO2016139362A1
· 2016
[cited by applicant]
WO WO2017031367A1
· 2017
[cited by applicant]
WO WO2017075399A1
· 2017
[cited by examiner]
WO WO2018191363A1
· 2018
[cited by applicant]
Gao et al., Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. Theranostics. Mar. 3, 2016;6(5):627-37. doi. 10.7150/thno.14792.
[cited by applicant]
Huis In't Veld et al., Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete response in a murine model of local and distant tumors. Cancer Immunol Immunoth…
[cited by applicant]
Kines et al., Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens. Cancer Immunol Res. Jun. 2021;9(6):693-706. doi. 10.1…
[cited by applicant]
Shitara K., Clinical Trials of Combination Therapy to Potentiate Efficacy of Immune Check Point Inhibitors. Int J Clin Exp Med. Jul. 30, 2016;258(5):471-479.
[cited by applicant]
Extended European Search Report for Application No. EP 18783979.0 mailed Dec. 7, 2020.
[cited by applicant]
Blackhall et al., Heparan sulfate proteoglycans and cancer. Br J Cancer. Oct. 19, 2001;85(8):1094-8. doi: 10.1054/bjoc.2001.2054.
[cited by applicant]
Davies et al., Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res. Aug. 1, 2004;10(15):5178-86. doi:10.1158/1078-0432.CCR-03-0103.
[cited by applicant]
Mitsunaga et al., Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. Nov. 6, 2011;17(12):1685-91. doi: 10.1038/nm.2554.
[cited by applicant]
Sanderson, Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. Apr. 2001;12(2):89-98. doi: 10.1006/scdb.2000.0241.
[cited by applicant]
International Preliminary Report on Patentability mailed Aug. 18, 2011 for Application PCT/IB2010/002654.
[cited by applicant]
International Search Report and Written Opinion mailed Jun. 28, 2018 for Application PCT/US2018/027080.
[cited by applicant]
International Preliminary Report on Patentability mailed Oct. 24, 2019 for Application PCT/US2018/027080.
[cited by applicant]
[No Author Listed] Bac-to-Bac Baculovirus Expression System. An efficient site-specific transposition system to generate baculovirus for high-level expression of recombinant proteins. Sep. 4, 2010. Retrieved from the In…
[cited by applicant]
[No Author Listed] GenBank Accession No. P03101, Major Capsid Protein L1, Jan. 11, 2011.
[cited by applicant]
Alvarez, Insertion de sequences peptidiques dans la proteine majeure de capside du papillomavirus de type 16: application au ciblage pulmonaire de vecteurs derives et a la production d'un vaccine chimerique. Thesis. Uni…
[cited by applicant]
Bergsdorf et al., Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett. Feb. 11, 2003;536(1-3): 120-4.
[cited by applicant]
Bousarghin et al., Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther. Feb. 2009;8(2):357-65. Epub J…
[cited by applicant]
Brasch et al., Encapsulation of phthalocyanine supramolecular stacks into virus-like particles. J Am Chem Soc. May 11, 2011;133(18):6878-81. doi: 10.1021/ja110752u. Epub Apr. 20, 2011.
[cited by applicant]
Brumfield et al., Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J Gen Virol. Apr. 2004;85(Pt…
[cited by applicant]
Buck et al., Efficient intracellular assembly of papillomaviral vectors. J Virol. Jan. 2004;78(2):751-7.
[cited by applicant]
Buck et al., Production of papillomavirus-based gene transfer vectors. Current Protocols in Cell Biology. 26.1.1-26.1.19, Dec. 2007.
[cited by applicant]
Butz et al., siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. Sep. 4, 2003;22(38):5938-45.
[cited by applicant]
Canti et al., Photodynamic therapy with photoactivated aluminum disulfonated phthalocyanine and cellular immune response. Proc. SPIE 3254, Laser-Tissue Interaction IX (May 13, 1998); doi: 10.1117/12.308158. Event: BIOS …
[cited by applicant]
Carpentier et al. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies. J Med Viral. Dec. 2…
[cited by applicant]
Carpentier et al., Cell targeting for CF gene therapy: Identification of a new specific cell ligand and selection of infectious papillomavirus mutants. J Cystic Fibro. Jun. 1, 2009;8:S31.
[cited by applicant]
Carpentier, Retargeting human papillomavirus-mediated gene transfer to human airway epithelial cells. J Cystic Fibro. Jun. 1, 2010;9:S17.
[cited by applicant]
Carter et al., Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol. Nov. 2003;77(21):11625-32.
[cited by applicant]
Carter et al., Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol. May 2006;80(10):4664-72.
[cited by applicant]
Christensen et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology. Sep. 1, 1996;223(1):174-84.
[cited by applicant]
Cohen et al., Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids. J Photochem Photobiol B. Apr. 5, 2013;121:67-74. doi: 10.1016/j.jphotobiol.2013.02.013. Epub Feb. 28, 2013.
[cited by applicant]
Combita et al., Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett. Oct. 16, 2001;204(1):183-8.
[cited by applicant]
Cook et al., Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from
[cited by applicant]
Culp et al., Papillomavirus particles assembled in 293TT cells are infectious in vivo. J Virol. Nov. 2006;80(22):11381-4. Epub Aug. 30, 2006.
[cited by applicant]
Douglas et al., Protein engineering of a viral cage for constrained nanomaterials synthesis. Adv Mater. Mar. 12, 2002;14(6):415-8.
[cited by applicant]
Elbashir et al., Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. Feb. 2002;26(2):199-213.
[cited by applicant]
Ewers et al., GMI structure determines SV40-induced membrane invagination and infection. Nat Cell Biol. Jan. 2010;12(1):11-20; sup pp. 1-12. doi: 10.1038/ncb1999. Epub Dec. 20, 2009.
[cited by applicant]
Finnen et al., Interactions between papillomavirus L1 and L2 capsid proteins. J Viral. Apr. 2003;77(8):4818-26.
[cited by applicant]
Feltkamp et al., Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. Sep. 1993;23(9):2242-9.
[cited by applicant]
Fleury et al., Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci. Jul. 2009;18(7):1425-38.
[cited by applicant]
Gaden et al., Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. J Virol. Jul. 2004;78(13):7227-47.
[cited by applicant]
Gillitzer et al., Controlled ligand display on a symmetrical protein-cage architecture through mixed assembly. Small. Aug. 2006;2(8-9):962-6.
[cited by applicant]
Hagensee et al. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the Ll and L2 capsid proteins. Journal of virology. Jan. 1, 1993;67(1):315-22.
[cited by applicant]
Jiang et al., Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides. 2004 Winter;14(4):239-48.
[cited by applicant]
Jiang et al., Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs. Methods Mol Biol. 2005;292:401-20.
[cited by applicant]
Jiang et al., Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. Sep. 5, 2002;21(39):6041-8.
[cited by applicant]
Jost et al., A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett. Feb. 2, 2001;489(2-3):263-9.
[cited by applicant]
Kawana et al., In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol. Dec. 1998;72(12):10298-300.
[cited by applicant]
Kines et al., An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma. Mol Cancer Ther. Feb. 2018;17(2):565-574. doi: 10.1158/1535-7163.MCT-17-0953. Epub Dec. 14, 2017.
[cited by applicant]
Kines et al., Human papillomavirus capsids preferentially bind and infect tumor cells. Int J Cancer. Feb. 15, 2016;138(4):901-11. doi: 10.1002/ijc.29823. Epub Oct. 27, 2015.
[cited by applicant]
Kirnbauer et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. Journal of virology. Dec. 1, 1993;67(12):6929-36.
[cited by applicant]
Kirnbauer et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences. Dec. 15, 1992;89(24):12180-4.
[cited by applicant]
Lavelle et al., The disassembly, reassembly and stability of CCMV protein capsids. J Virol Methods. Dec. 2007; 146(1-2):311-6. Epub Sep. 4, 2007.
[cited by applicant]
Lee et al., Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine. Sep. 2006;2(3):137-49.
[cited by applicant]
Leong et al., Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat Protoc. Aug. 2010;5(8):1406-17. doi: 10.1038/nprot.2010.103. Epub Jul. 8, 2010.
[cited by applicant]
Li et al, Expression of the human papillomavirus type 11 LI capsid protein in
[cited by applicant]
Li et al, Trackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging. Theranostics. 2011;1:371-80. Epub Nov. 18, 2011.
[cited by applicant]
Lin et al., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. Jan. 1, 1996;56(1):21-6.
[cited by applicant]
Melero et al., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. Aug. 2015;15(8):457-72. doi: 10.1038/nrc3973.
[cited by applicant]
Mitsunaga et al., In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system. Cancer Prev Res (Phila). May 2011;4(5):767-73. doi: 10.1158/194…
[cited by applicant]
Oh et al., Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology. Oct. 25, 2004;328(2):266-73.
[cited by applicant]
Pedersen et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Journal of Adolescent Health. Jun. 30, 2007;40(6):564-71.
[cited by applicant]
Peng et al., Construction and production of fluorescent papillomavirus-like particles. J Tongji Med Univ. 1999;19(3):170-4, 180.
[cited by applicant]
Pinto et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Journal of Infectious Diseases. Jul. 15, 2003;188(2):327-38.
[cited by applicant]
Pyeon et al., Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A. Jun. 28, 2005;102(26):9311-6. Epub Jun. 15, 2005.
[cited by applicant]
Raja et al., Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules. May-Jun. 2003;4(3):472-6.
[cited by applicant]
Rhee et al., Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules. Aug. 13, 2012;13(8):2333-8. doi: 10.1021/bm300578p. Epub Jul. 24, 2012. Author manuscript.
[cited by applicant]
Rose et al. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. Journal of Virology. Apr. 1, 1993;67(4):1936-44.
[cited by applicant]
Rudolf et al., Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. May 15, 2001;166(10):5917-24.
[cited by applicant]
Ruehlmann et al., MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. Dec. 1, 2001;61(23):8498-503.
[cited by applicant]
Ryding et al., Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol. Mar. 2007;88(Pt 3):792-802.
[cited by applicant]
Sadeyen et al., Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutr…
[cited by applicant]
Schädlich et al., Refining HPV 16 L1 purification from
[cited by applicant]
Singh, Tumor targeting using canine parvovirus nanoparticles. Curr Top Microbiol Immunol. 2009;327:123-41.
[cited by applicant]
Speir et al., Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and cryo-electron microscopy. Structure. Jan. 15, 1995;3(1):63-78.
[cited by applicant]
Stephanopoulos et al., Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. ACS Nano. Oct. 26, 2010;4(10):6014-20. doi: 10.1021/nn1014769.
[cited by applicant]
Touze et al., In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. Mar. 1, 1998;26(5):1317-23.
[cited by applicant]
Touze et al., The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol. Jul. 1998;36(7):2046-51.
[cited by applicant]
Touzé et al., The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity. FEMS Microbiol Lett. Aug. 1, 2000;189(1):121-7.
[cited by applicant]
Uchida et al., Biological Containers: Protein Cages as Multifunctional Nanoplatforms. Adv Mater. 2007;19:1025-42.
[cited by applicant]
Varsani et al., Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol. Aug. 2003;77(15):8386-93.
[cited by applicant]
Vaysse et al., Improved transfection using epithelial cell line-selected ligands and fusogenic peptides. Biochim Biophys Acta. Jul. 26, 2000;1475(3):369-76.
[cited by applicant]
Wang et al., Insertion of a targeting peptide on capsid surface loops of human papillomavirus type-16 virus-like particles mediate elimination of anti-dsDNA Abs-producing B cells with high efficiency. J Immunother. Jan.…
[cited by applicant]
Wang et al., Expression of Human Papillomavirus Type 6 L1 and L2 Isolated in China and Self Assembly of Virus-like Particles by the Products. Acta Biochimica et Biophysica Sinica. 2003;35(1):27-34. 10 pages.
[cited by applicant]
Wang et al., Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes. J Gen Virol. Jun. 2003;84(Pt 6):1493-7.
[cited by applicant]
White et al., Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum Gene Ther. Dec. 2008;19(12):1407-14.
[cited by applicant]
Willits et al., Effects of the cowpea chlorotic mottle bromovirus beta-hexamer structure on virion assembly. Virology. Feb. 15, 2003;306(2):280-8.
[cited by applicant]
Xu et al., Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol. Nov. 2006;151(11):2133-48. Epub Jun. 22, 2006.
[cited by applicant]
Yoshinouchi et al., In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther. Nov. 2003;8(5):762-8.
[cited by applicant]
Zhang et al. Expression of Human Papillomavirus Type 16 L1 Protein in
[cited by applicant]
Zhou et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. Nov. 1, 1991;185(1):251-7.
[cited by applicant]
U.S. Appl. No. 13/264,213, filed Mar. 2, 2012, Coursaget et al., Granted.
[cited by applicant]
U.S. Appl. No. 15/636,112, filed Jun. 28, 2017, Coursaget et al., Granted.
[cited by applicant]
U.S. Appl. No. 16/204,019, filed Nov. 29, 2018, Coursaget et al., Published.
[cited by applicant]
U.S. Appl. No. 14/376,408, filed Aug. 1, 2014, de los Pinos et al., Granted.
[cited by applicant]
U.S. Appl. No. 15/615,485, filed Jun. 6, 2017, de los Pinos et al., Granted.
[cited by applicant]
U.S. Appl. No. 15/824,685, filed Nov. 28, 2017, de los Pinos et al., Granted.
[cited by applicant]
U.S. Appl. No. 16/376,435, filed Apr. 5, 2019, de los Pinos et al., Allowed.
[cited by applicant]
U.S. Appl. No. 15/023,169, filed Mar. 18, 2016, de los Pinos et al., Granted.
[cited by applicant]
U.S. Appl. No. 16/143,147, filed Sep. 26, 2018, de los Pinos et al., Allowed.
[cited by applicant]
U.S. Appl. No. 15/772,134, filed Apr. 30, 2018, Lobb et al., Published.
[cited by applicant]
PCT/IB2010/002654, Aug. 8, 2011, International Preliminary Report on Patentability.
[cited by applicant]
PCT/US2018/027080, Jun. 28, 2018, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2018/027080, Oct. 24, 2019, International Preliminary Report on Patentability.
[cited by applicant]